MSAC application for Hemlibra

HFA has been asked about progress of the Medical Services Advisory Committee (MSAC) consideration for government funding for emicizumab (Hemlibra®). This is a new non-clotting factor product registered for prophylaxis treatment for people with moderate to severe factor VIII deficiency with or without inhibitors.

MSAC previously considered emicizumab under MSAC application 1510. Further consideration is now underway under a different MSAC application (1579, which specifically addresses emicizumab for non-inhibitor patients).

HFA has been invited for stakeholder input on MSAC application 1579 by 30 May 2019, which we will do, using feedback provided by our members.

Individuals may also provide feedback and comments directly to MSAC during the MSAC process – click here for more information. MSAC advises that your input should be via a maximum of two A4 pages to . Make sure that you type the application number 1579 at the start of your comments and in the subject heading of your email.

Latest stories

Welcome to our new website

HFA has a new website! You’ll find all of the same great content and information, but in brand new packaging. Over the past 12 months we’ve been working hard with the team at Heartburst to modernise the HFA website. We have great plans for new features to be added in 2024, so please be patient with us while we’re in the process of developing them.

Read More

Join the HFA community

Sign up for the latest news, events and our free National Haemophilia magazine

Skip to content